RxDoctor Payments Data

Emma Ellman-Groves, PA

Physician Assistant · Newark, DENPI 1457815771

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Among physician assistant clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,377in general payments, 2019–2025

Across 249 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$744
  • Johnson & Johnson$457
  • Sanofi$353
  • Regeneron Healthcare Solutions, Inc.$324
  • Ardelyx, Inc.$317
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$4,31599%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,377 in reported general payments places this provider in the 95th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Medicare billing

Part B allowed, 2024
$36,781
Medicare patients
247
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide93$58,377
CreonLipase/Protease/Amylase13$19,617
Pantoprazole Sodium237$4,765
Omeprazole374$3,323
Mesalamine13$3,121
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg112$3,037
Esomeprazole Magnesium91$2,827
Famotidine168$1,887
MesalamineMesalamine W/Cleansing Wipes11$845
Ondansetron OdtOndansetron29$308
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$232
Dicyclomine Hcl19$200
Metoclopramide Hcl15$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,008$77,994106 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →